Privacy Statement

Galderma Laboratories, L.P. Internet Privacy Policy. Galderma respects the privacy of every individual visiting our Web sites. Galderma's Privacy Policy, outlining the information, Galderma collects and how Galderma uses such information is as follows:

Personally Identifiable Information

Galderma collects personally identifiable information (such as name, address, telephone/fax number and e-mail address) only when voluntarily provided by a visitor to our Web sites. Galderma does not sell, rent or otherwise make available any personally identifiable information submitted by visitors to our Web site to any third parties. This information will not be used for any direct marketing or unsolicited follow-up unless we have previously informed you of this possible use and you have given us your express permission when submitting it. After obtaining your consent, Galderma may use this information for such purposes as:

  • Sending you paper publications or other correspondence
  • Sending you e-mail press releases or notification
  • Delivering goods or prizes

Only authorized Galderma staff or our agents (who have agreed to keep information secure) have access to personally identifiable information.

Galderma does make use of non-personally identifiable statistical information collected from users (browser type, geographical location, age, gender) for optimization of its sites as part of its continual internal review process and in a general way to learn more about its clients. This information will not be disclosed to third parties by Galderma. This data will only be used for the stated purpose and will not be used for any unsolicited communication unless you give us permission.

Log Files

We use IP addresses to analyze trends, administer the site, track user's movements, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Cookies

Galderma does use tracking technology (known as 'cookies') which deposits certain bits of information on your hard drive. Cookies allow us to track and target your interests to tailor our sites to suit your needs better.

Children

Children and young people under the age of 16 are requested to get permission from their parent or guardian before they submit personal data to Galderma Web sites.

Links

Links from this site may take you to other sites. Please be aware that we are not responsible for the privacy practices of such other sites. We advise you to check their privacy policies yourself before submitting any personally identifiable information.

Changes

By using this Web site, you signify your agreement to the terms and conditions of this Privacy Policy. If you do not agree to these terms and conditions, please do not disclose any personally identifiable information though this Web site. This policy may be modified from time to time, and changes will be communicated promptly on this page. Please contact us for more information on this policy.

Please contact us for more information on this policy.
Webmaster
Galderma Laboratories, L.P.
webmaster@galderma.com

IMPORTANT SAFETY INFORMATION

Indication: METROGEL® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with METROGEL 1% were nasopharyngitis, upper respiratory tract infection, and headache. Other adverse experiences reported when using topical metronidazole include skin irritation, transient redness, metallic taste, tingling or numbness of the extremities and nausea. Warnings/Precautions: METROGEL 1% should not be used by patients who are allergic to metronidazole or any ingredient in METROGEL 1%. Avoid contact of METROGEL 1% with the eyes as it may cause tearing. METROGEL 1% should be used with caution in patients with evidence of, or a history of, blood dyscrasia, and with patients taking blood thinning agents as they may experience prolonged prothrombin times. METROGEL 1% treatment should be discontinued if numbness or paresthesia of any extremity should occur.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.